Peptide Glossary: What BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon Actually Do

Peptides are short chains of amino acids that can act as biological signals, influencing how cells communicate, respond to stress, regulate inflammation, use energy, or repair damaged tissue. The growing interest in experimental peptides has also created considerable confusion about what each compound is supposed to do and what has actually been demonstrated. The AlphaMD peptide hub provides a central place to explore the latest research, regulatory developments, potential benefits, and unresolved risks.

Here is the quick answer: BPC-157 and TB-500 are primarily associated with tissue-repair research, KPV with inflammatory signaling, MOTS-c with metabolism, Semax with neurological pathways, and Epitalon with circadian rhythms and cellular-aging research. However, being associated with a biological pathway is not the same as being proven to improve health outcomes.

None of these six peptides is currently an FDA-approved medication in the United States. Human evidence is limited or absent for many of the claims made online, and standardized dosages, long-term safety profiles, contraindications, and medication interactions have not been established.

The Six Peptides at a Glance

BPC-157

Main area of research: Tissue and gastrointestinal repair

What it may influence: Cell migration, blood-vessel formation, tendon healing, intestinal protection, and other tissue-repair pathways.

State of human evidence: Evidence comes primarily from laboratory and animal research. Adequate clinical trials have not established that BPC-157 improves injury recovery or gastrointestinal conditions in humans.

KPV

Main area of research: Inflammation and immune signaling

What it may influence: Inflammatory pathways involving the gut, skin, epithelial cells, and immune cells.

State of human evidence: There is no adequate clinical evidence establishing KPV as a treatment for inflammatory bowel disease, skin conditions, autoimmune disease, or generalized inflammation.

TB-500

Main area of research: Wound and soft-tissue repair

What it may influence: Actin activity, cell movement, collagen deposition, blood-vessel formation, and wound closure.

State of human evidence: Most supporting evidence involves animal research, laboratory models, or studies of full-length thymosin beta-4 rather than TB-500 itself.

MOTS-c

Main area of research: Metabolism and cellular stress

What it may influence: Glucose utilization, metabolic signaling, skeletal-muscle activity, insulin sensitivity, and cellular responses to energy stress.

State of human evidence: Research remains early. MOTS-c has not been established as a treatment for obesity, diabetes, fatigue, metabolic disease, or aging.

Semax

Main area of research: Neurological function

What it may influence: Brain connectivity, neurotrophic signaling, inflammation within the nervous system, and responses to reduced blood flow or oxygen.

State of human evidence: Some small human studies have been conducted, but the evidence is insufficient to establish reliable benefits for cognition, mood, stroke recovery, or neurological disease.

Epitalon

Main area of research: Sleep, circadian biology, and cellular aging

What it may influence: Melatonin-related rhythms, telomerase activity, telomere length, gene expression, and cellular-aging pathways.

State of human evidence: Evidence consists mainly of cell studies, animal research, and limited or poorly established human research. Epitalon has not been proven to slow human aging or extend lifespan.

The FDA reviewed these substances in July 2026 for possible inclusion on the Section 503A Bulks List. The reviewed uses included ulcerative colitis, wound healing, inflammatory conditions, obesity, osteoporosis, cerebral ischemia, migraine, trigeminal neuralgia, and insomnia.

This regulatory process concerns whether qualifying pharmacies may eventually be permitted to use particular bulk substances for patient-specific compounding. It is not FDA drug approval. Readers can review the FDA’s official peptide meeting materials.

1. What Does BPC-157 Do?

BPC-157 is a synthetic peptide containing 15 amino acids. It has become widely known as a recovery peptide because animal and laboratory studies have investigated its effects on tendons, ligaments, muscles, nerves, blood vessels, and gastrointestinal tissue.

What BPC-157 Appears to Do in Research

In laboratory and animal models, BPC-157 has been reported to influence:

• Tendon-cell migration and survival
• Formation of new blood vessels
• Tendon-to-bone healing
• Gastrointestinal tissue protection
• Wound-healing pathways
• Inflammatory signaling

A frequently cited tendon study found that BPC-157 promoted tendon outgrowth, cell survival, and cell migration in experimental models. These findings help explain why BPC-157 is marketed for injury recovery, but the study did not establish that it repairs tendon injuries in people. Readers can review the BPC-157 tendon study.

What Is Actually Established in Humans?

There are no adequate randomized clinical trials proving that BPC-157 heals human tendons, ligaments, muscles, joints, ulcers, or inflammatory bowel disease. There is also no FDA-approved BPC-157 dosage, route of administration, treatment schedule, or safety-monitoring protocol.

Most of its reputation comes from animal studies, laboratory experiments, case reports, and personal testimonials. Those sources may generate research questions, but they cannot establish effectiveness or long-term safety.

For a more detailed analysis, read about BPC-157 benefits, risks, side effects, and FDA status.

Plain-English takeaway: BPC-157 appears to activate several repair-related processes in animals and cells. It has not been proven to accelerate injury recovery in people.

2. What Does KPV Do?

KPV is a three-amino-acid peptide made from lysine, proline, and valine. It represents the final three amino acids of alpha-melanocyte-stimulating hormone, commonly abbreviated as alpha-MSH.

Alpha-MSH participates in inflammatory and immune signaling. KPV has attracted interest because it may retain some of alpha-MSH’s anti-inflammatory activity without producing its pigment-related effects.

What KPV Appears to Do in Research

Cell and animal studies suggest that KPV may influence:

• Pro-inflammatory signaling molecules
• Intestinal epithelial inflammation
• Immune-cell activity
• Skin inflammation
• Wound-healing responses
• Certain pathways involved in experimental colitis

In mouse models of inflammatory bowel disease, KPV reduced several measures of intestinal inflammation. Researchers have also studied how intestinal peptide transporters may help move KPV into epithelial and immune cells. Readers can review the KPV inflammatory-bowel-disease study.

What Is Actually Established in Humans?

The FDA has stated that it has not identified human exposure data involving KPV drug products administered through any route. Researchers therefore do not have adequate evidence defining its clinical benefits, common side effects, medication interactions, effective dosage, or long-term risks.

KPV is sometimes marketed for ulcerative colitis, Crohn’s disease, eczema, psoriasis, acne, rosacea, and general inflammation. None of these is an FDA-approved indication, and findings from mouse models should not be presented as proof of effectiveness in patients.

Read the complete AlphaMD guide to KPV benefits, risks, and side effects.

Plain-English takeaway: KPV may reduce certain inflammatory signals in cells and animal models. It has not been established as a human treatment for gut, skin, or autoimmune disease.

3. What Does TB-500 Do?

TB-500 is generally identified as the seven-amino-acid sequence LKKTETQ, an actin-binding fragment associated with thymosin beta-4.

This distinction is important. Full-length thymosin beta-4 is a naturally occurring 43-amino-acid peptide that has been studied more extensively. TB-500 is a much smaller fragment. Research involving full-length thymosin beta-4 cannot automatically be treated as evidence for TB-500.

What TB-500 Appears to Do in Research

Actin is a structural protein that helps cells move, divide, and change shape. These processes are necessary during wound repair.

Experimental research involving thymosin beta-4 or the LKKTETQ fragment suggests possible effects on:

• Cell migration
• Wound closure
• Collagen deposition
• Formation of new blood vessels
• Tissue remodeling
• Inflammatory responses
• Repair in aged or diabetic animal models

One mouse study found that both full-length thymosin beta-4 and a synthetic peptide containing its actin-binding domain promoted dermal wound repair. The research involved animals, not patients receiving commercially marketed TB-500. Readers can review the thymosin beta-4 fragment study.

What Is Actually Established in Humans?

There is no adequate human clinical evidence demonstrating that TB-500 repairs torn muscles, tendons, ligaments, or surgical wounds. The FDA has also reported that it has not identified human exposure data involving drug products containing the thymosin beta-4 LKKTETQ fragment.

Many articles and advertisements blur the distinction between TB-500 and full-length thymosin beta-4. That can make the evidence appear stronger than it is.

Explore the differences in the AlphaMD guide to TB-500 benefits, risks, and side effects.

Plain-English takeaway: TB-500 is intended to reproduce a repair-related region of thymosin beta-4. Animal evidence suggests that the region participates in cell movement and wound repair, but TB-500 has not been proven to heal sports injuries in people.

4. What Does MOTS-c Do?

MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA. Mitochondria help cells convert nutrients into usable energy, but they also communicate with the rest of the cell and respond to metabolic stress.

MOTS-c is therefore often described as a mitochondrial-derived peptide or a metabolic-signaling peptide.

What MOTS-c Appears to Do in Research

Laboratory and animal research suggests that MOTS-c may influence:

• Glucose uptake and utilization
• Insulin sensitivity
• Skeletal-muscle metabolism
• Fat metabolism
• AMPK-related energy signaling
• Cellular responses to metabolic stress
• Exercise adaptation
• Age-related metabolic changes

The original discovery research found that MOTS-c affected folate and purine metabolism, activated AMPK, and improved metabolic measurements in mouse models of obesity and insulin resistance. Readers can review the original MOTS-c study.

Is MOTS-c a Weight-Loss Drug?

No. MOTS-c is not an FDA-approved treatment for weight loss, obesity, diabetes, insulin resistance, osteoporosis, fatigue, or aging.

Animal findings have generated legitimate scientific interest, but they do not establish that injecting MOTS-c causes meaningful or safe weight loss in people. MOTS-c should not be described as a replacement for an FDA-approved GLP-1 medication, nutrition intervention, exercise program, or established diabetes treatment.

The FDA has said that it has not identified human exposure data involving drug products containing MOTS-c. Human studies measuring naturally occurring MOTS-c levels or biological responses to exercise are not the same as clinical trials of a manufactured MOTS-c drug.

Read more in the AlphaMD overview of MOTS-c benefits, risks, and side effects.

Plain-English takeaway: MOTS-c appears to help cells respond to metabolic stress in laboratory and animal research. It has not been established as a safe or effective weight-loss, energy, or longevity treatment.

5. What Does Semax Do?

Semax is a synthetic peptide containing seven amino acids. It was developed from the ACTH 4-10 fragment, although it is not the same as full-length adrenocorticotropic hormone and is not intended to produce ACTH’s primary cortisol-stimulating activity.

Semax has been used and studied in Russia, commonly through intranasal administration. It is promoted online as a nootropic for focus, memory, mood, stress resilience, and neurological recovery.

What Semax Appears to Do in Research

Animal and laboratory studies suggest that Semax may influence:

• Brain-derived neurotrophic factor, or BDNF
• Neuroplasticity-related pathways
• Inflammatory signaling in the nervous system
• Dopamine and serotonin activity
• Responses to reduced blood flow and oxygen
• Oxidative stress
• Neural-cell survival

Small human brain-imaging studies have reported short-term changes in resting-state functional connectivity following intranasal Semax. However, a change on an fMRI scan does not prove improved memory, focus, productivity, mood, or daily functioning. Readers can review the human Semax brain-imaging study.

Does Semax Improve Focus or Treat Stroke?

There is not enough high-quality evidence to conclude that Semax reliably improves cognition or treats stroke, migraine, trigeminal neuralgia, depression, anxiety, ADHD, or brain injury.

The available human studies are generally small, short, and limited by incomplete reporting. Some were conducted under a different regulatory system, and several have not been available in sufficient detail for complete independent evaluation.

Semax should never be used in place of emergency treatment for a possible stroke or another acute neurological condition.

Read AlphaMD’s detailed guide to Semax benefits, risks, and side effects.

Plain-English takeaway: Semax may affect neurological signaling and brain-network activity. Researchers have not established that these changes translate into reliable cognitive or medical benefits.

6. What Does Epitalon Do?

Epitalon, also spelled Epithalon, is a synthetic peptide containing four amino acids: alanine, glutamic acid, aspartic acid, and glycine. Its sequence is commonly abbreviated as AEDG.

Epitalon is promoted primarily in longevity circles for sleep, melatonin production, telomere support, and slower aging.

What Epitalon Appears to Do in Research

Researchers have investigated Epitalon’s possible effects on:

• Melatonin production
• Circadian hormone rhythms
• Telomerase activity
• Telomere length
• Cellular-aging pathways
• Gene expression
• Oxidative stress
• Animal lifespan

An older study in aging monkeys reported changes in melatonin and cortisol regulation after Epitalon administration. The study did not establish that Epitalon treats human insomnia or improves long-term sleep outcomes. Readers can review the Epitalon monkey study.

Laboratory studies have also reported telomerase activation or telomere-length changes in cultured human cells. A cell line is not a person, and telomere elongation in a laboratory does not prove slower aging, better health, or longer life. Readers can review the Epitalon telomere cell study.

Does Epitalon Slow Aging?

There is no reliable clinical evidence that Epitalon slows human aging, reverses biological age, prevents age-related disease, or extends lifespan.

Telomere biology is also more complicated than the idea that longer is always better. Telomerase activity helps maintain telomeres, but many cancer cells also use telomerase or other telomere-maintenance systems to continue dividing.

This does not prove that Epitalon causes cancer. It does mean that long-term manipulation of telomere biology requires careful research rather than assumptions based on a single laboratory marker.

Read the complete AlphaMD guide to Epitalon benefits, risks, and side effects.

Plain-English takeaway: Epitalon has affected melatonin-related rhythms in animals and telomere-related mechanisms in cultured cells. It has not been proven to improve human sleep, slow aging, or extend lifespan.

Are These Six Peptides FDA Approved?

No. BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon are not FDA-approved medications.

The July 2026 Pharmacy Compounding Advisory Committee review concerned possible inclusion of their free-base and acetate forms on the Section 503A Bulks List. Even if a substance is eventually placed on that list, the resulting compounded medication does not become FDA approved.

The FDA does not review compounded drugs for safety, effectiveness, or manufacturing quality in the same manner as commercially approved medications before they are dispensed.

Compounding can serve an important medical role when an individual patient has a clinical need that cannot be met by an available approved product, but it is not a substitute for the conventional drug-approval process. Readers can learn how the FDA regulates bulk substances used under Section 503A.

What Are the Shared Risks?

The six peptides act on different biological pathways, but they share several major uncertainties.

Incomplete Human Safety Information

For many of these substances, researchers do not know:

• The most common adverse effects
• The frequency of serious reactions
• The safest route of administration
• The effective dosage range
• The maximum safe exposure
• The risks of repeated or long-term use
• Possible drug interactions
• Effects during pregnancy or breastfeeding
• Effects on fertility
• Risks in people with cancer, autoimmune disease, liver disease, or kidney disease

A lack of reported side effects does not demonstrate safety when controlled human exposure and adverse-event reporting are limited.

Product Identity and Potency

An online product labeled with a peptide name may contain:

• The wrong peptide
• An incorrect amino-acid sequence
• A free-base form instead of an acetate form
• Too much or too little active ingredient
• Degradation products
• Peptide aggregates
• Residual manufacturing chemicals
• Bacterial endotoxins
• Microbial contamination
• No active peptide at all

A certificate claiming high purity does not establish sterility, accurate dosing, appropriate storage, or suitability for human use.

Immune Reactions

Peptides, aggregates, impurities, or formulation ingredients may potentially trigger immune responses. Possible reactions could range from localized irritation to hypersensitivity or antibody formation. The actual rates for these six peptides are unknown.

The FDA has specifically identified unresolved concerns involving peptide characterization, aggregation, impurities, and immunogenicity for several of these substances. Readers can review the FDA’s safety concerns involving compounded bulk substances.

Delayed Medical Treatment

Using an experimental peptide can create additional risk when it delays diagnosis or established treatment.

Examples include:

• Using BPC-157 instead of evaluating a tendon rupture
• Using KPV instead of treating inflammatory bowel disease
• Using MOTS-c instead of addressing diabetes or obesity through established care
• Using Semax instead of obtaining emergency stroke treatment
• Using Epitalon instead of being evaluated for sleep apnea or chronic insomnia

How Should You Evaluate a Peptide Claim?

A responsible assessment begins with five questions.

1. Was the Research Performed in People?

Cell and animal studies can identify possible mechanisms. They cannot establish that a peptide produces the same result safely in humans.

2. Did the Study Examine the Exact Peptide?

Research involving full-length thymosin beta-4 is not automatically evidence for TB-500. Research involving Epithalamin, a complex pineal extract, is not automatically evidence for synthetic Epitalon.

3. Was a Meaningful Clinical Outcome Measured?

Changes in inflammatory markers, brain connectivity, gene expression, melatonin, or telomerase may be scientifically interesting. They do not necessarily mean that patients heal faster, think more clearly, sleep better, lose weight, or live longer.

4. Was There a Control Group?

Testimonials and uncontrolled studies cannot reliably separate a peptide’s effect from placebo responses, natural recovery, changes in training, other medications, or normal symptom variation.

5. Is the Product Coming Through a Legitimate Medical Pathway?

Products sold as “research use only” should not be assumed to be sterile, accurately labeled, or appropriate for human administration.

Peptide use should be discussed with a licensed medical provider who understands the evidence, alternatives, medical history, and applicable regulations.

Frequently Asked Questions

Which Peptide Is Used for Injury Recovery?

BPC-157 and TB-500 are the two peptides most commonly promoted for injury and soft-tissue recovery. Research has identified repair-related activity in cells and animals, but neither peptide has been proven through adequate clinical trials to heal human tendon, ligament, or muscle injuries.

Which Peptide Is Associated With Inflammation?

KPV is primarily studied for anti-inflammatory signaling. BPC-157 has also been examined in gastrointestinal and inflammatory animal models. Neither is an FDA-approved treatment for inflammatory bowel disease, autoimmune disease, or inflammatory skin conditions.

Which Peptide Is Associated With Metabolism and Weight Loss?

MOTS-c is associated with metabolic signaling, glucose use, insulin sensitivity, and exercise-related pathways. It is not an FDA-approved weight-loss medication, and it has not been proven to produce safe, clinically meaningful weight loss in humans.

Which Peptide Is Promoted for Focus and Memory?

Semax is commonly promoted as a cognitive peptide or nootropic. Small studies have reported changes in brain connectivity, but reliable improvements in focus, memory, mood, or work performance have not been established.

Which Peptide Is Promoted for Longevity?

Epitalon is widely promoted for telomere support and anti-aging. Laboratory findings involving telomerase and animal findings involving circadian biology do not prove that it slows human aging or extends lifespan.

Can These Peptides Be Stacked Together?

There are no established, FDA-approved stacking protocols for these six peptides. Combining experimental substances may increase uncertainty, create unrecognized interactions, and make it difficult to determine which product caused a benefit or adverse reaction.

Does an FDA Advisory Recommendation Mean a Peptide Is Approved?

No. An advisory committee provides recommendations to the FDA. The FDA retains authority over the final regulatory decision.

Inclusion on the Section 503A Bulks List would concern a possible pharmacy-compounding pathway and would not constitute FDA approval of the peptide as a medication.

Are Compounded Peptides Safer Than Research Chemicals?

A medication prepared by a properly licensed pharmacy under applicable standards may offer greater accountability and product traceability than an unverified research-chemical seller.

However, compounded drugs are not FDA approved, and better manufacturing oversight does not resolve unanswered questions about clinical effectiveness, dosing, or long-term safety.

The Bottom Line

BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon are not six versions of the same treatment.

Each is associated with a different area of experimental research:

• BPC-157: Gastrointestinal and tissue-repair pathways
• KPV: Inflammatory and immune signaling
• TB-500: Actin-related cell movement and wound repair
• MOTS-c: Metabolic and mitochondrial stress signaling
• Semax: Neurological and neurotrophic pathways
• Epitalon: Circadian and telomere-related biology

The science behind these peptides ranges from preliminary cell experiments to animal studies and small human investigations. None currently has the level of clinical evidence, standardized dosing, safety characterization, or regulatory review expected of an FDA-approved medication.

The most accurate description is not that these peptides “heal,” “burn fat,” “boost the brain,” or “reverse aging.” It is that researchers have identified mechanisms worth studying, while major questions about real-world benefits and risks remain unanswered.

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice or create a medical-provider relationship. It is not intended to diagnose, treat, cure, or prevent any disease. BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon are not currently FDA-approved medications. Speak with a licensed medical provider before using any medication, peptide, supplement, or injectable product.